Background and purpose Although the main clinical features of COVID-19 infection are
pulmonary, several associated neurological signs, symptoms and diseases are emerging.
The incidence and characteristics of neurological complications are unclear. For this
reason, the European Academy of Neurology (EAN) core COVID-19 Task Force initiated
a survey on neurological symptoms observed in patients with COVID-19 infection. Methods
A 17-question online survey was made available on the EAN website and distributed
to EAN members and other worldwide physicians starting on 9 April 2020. Results By
27 April 2020, proper data were collected from 2343 responders (out of 4199), of whom
82.0% were neurologists, mostly from Europe. Most responders (74.7%) consulted patients
with COVID-19 mainly in emergency rooms and in COVID-19 units. The majority (67.0%)
had evaluated fewer than 10 patients with neurological manifestations of COVID-19
(neuro COVID-19). The most frequently reported neurological findings were headache
(61.9%), myalgia (50.4%), anosmia (49.2%), ageusia (39.8%), impaired consciousness
(29.3%) and psychomotor agitation (26.7%). Encephalopathy and acute cerebrovascular
disorders were reported at 21.0%. Neurological manifestations were generally interpreted
as being possibly related to COVID-19; they were most commonly recognized in patients
with multiple general symptoms and occurred at any time during infection. Conclusion
Neurologists are currently and actively involved in the management of neurological
issues related to the COVID-19 pandemic. This survey justifies setting up a prospective
registry to better capture the prevalence of patients with neuro COVID-19, neurological
disease characteristics and the contribution of neurological manifestations to outcome.
